Multiple Sclerosis Article

CBD and Multiple Sclerosis: What You Need to Know

Source: 
https://multiplesclerosisnewstoday.com

Link: 
https://multiplesclerosisnewstoday.com/news-posts/2019/09/20/cbd-oil-and-multiple-sclerosis/

Article Summary:
Interest in the use of cannabidiol (CBD) and medical marijuana for multiple sclerosis (MS) is growing. A 2017 survey by the National Multiple Sclerosis Society revealed that 66% of MS patients were using cannabis for symptom management, while a 2016 Canadian survey found that 50% of MS patients would consider cannabis use if it were legally and scientifically validated. CBD, a non-psychoactive compound from the Cannabis sativa plant, interacts with the body’s endocannabinoid receptors and is thought to modulate their response, though its mechanisms are still under study.

CBD is regulated differently from THC, the psychoactive compound in marijuana, and its legality varies by state and country. In the U.S., CBD derived from hemp is federally legal, but state laws differ. Europe and the U.K. generally allow CBD use, while Canada’s regulations are more complex despite the legalization of recreational cannabis.

CBD can be taken in various forms, including oils, capsules, sprays, and topical applications. Concerns over vaping, particularly formulations containing THC and harmful additives, have led health authorities to advise against it. The effectiveness of different CBD formulations for MS symptoms is still debated.

Some evidence suggests that a 1:1 ratio of CBD to THC may reduce pain and muscle spasms in MS patients, but more research is needed to confirm the benefits and safety of CBD products. The variability in product quality and labeling accuracy complicates consistent dosing and effectiveness assessments. Side effects of CBD can include dry mouth, diarrhea, reduced appetite, and fatigue, and it can interact with other medications. Consultation with a healthcare provider is crucial before using CBD for MS.

While the FDA has approved some CBD-based medications for epilepsy and AIDS-related symptoms, it has not yet approved any for MS. In the U.K. and other European countries, Sativex (nabiximols) is approved for treating MS-related muscle spasms, and clinical trials are underway in the U.S.